MicroRNA-125b As a Valuable Predictive Marker for Outcome After Autologous Hematopoietic Stem Cell Transplantation

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2023 Mar 3

PMID 36869286

Authors

Mohammad Rafiee

Fatemeh Amiri

Mohammad Hossein Mohammadi

Abbas Hajifathali

Affiliations

Soon will be listed here.

Abstract

Background: Relapse is a frequent occurrence in autologous hematopoietic stem cell transplantation (AHSCT), and early relapse after AHSCT results in poor survival and low quality of life. Predictive marker determination for AHSCT outcomes could be helpful in the prevention of relapse through personalized medicine. Here the predictive value of circulatory microRNAs (miRs) expression for AHSCT outcomes was studied.

Methods: 50 MM and lymphoma candidates for AHSCT participated in this study. Two plasma samples were obtained before AHSCT from each candidate; one before mobilization and the other after conditioning. Extracellular vesicles (EVs) were isolated by ultracentrifugation. miR-125b, miR-126, miR-150, and miR-155 expression were analyzed in both plasma and EVs using real time polymerase chain reaction analysis. Other data related to AHSCT and its outcomes were also collected. The predictive value of miRs and other factors for outcomes was assessed by multi-variant analysis.

Results: By 90 weeks follow up after AHSCT, multi-variant and ROC analysis showed miR-125b as a predictive marker for relapse, high lactate dehydrogenase (LDH), and high erythrocyte sedimentation rate (ESR). The cumulative incidence of relapse, high LDH, and high ESR increased with an increase in circulatory miR-125b expression.

Conclusion: miR-125b could be applicable in prognosis evaluation and also create a possible new targeted therapy opportunity for enhanced outcomes and survival after AHSCT.

Trial Registration: The study was retrospectively registered. Ethic code No: IR.UMSHA.REC.1400.541.

Citing Articles

Harnessing the power of exosomes for diagnosis, prognosis, and treatment of hematological malignancies.

Mohseni A, Salehi F, Rostami S, Hadiloo K, Hashemi M, Baridjavadi Z Stem Cell Res Ther. 2025; 16(1):6.

PMID: 39773361 PMC: 11708188. DOI: 10.1186/s13287-024-04125-0.

Heparin-induced thrombocytopenia-II in hospitalized patients with surgery or deep vein thrombosis.

Gomar N, Abbasi Garavand T, Amiri F, Goodarzi A, Hashemi S Am J Blood Res. 2024; 14(3):14-21.

PMID: 39582770 PMC: 11578861. DOI: 10.62347/JMFO7582.

Pro-Oxidant/ Antioxidant Balance Correlates with Red Blood Cell Indices and Anemia Severity in the Anemic Patients.

Mohammad Shafiee S, Amiri F, Yousefi F, Akbari Nasab N Rep Biochem Mol Biol. 2024; 12(4):609-618.

PMID: 39086594 PMC: 11288238. DOI: 10.61186/rbmb.12.4.609.

High serum miR-223-3p expression level predicts complete response and prolonged overall survival in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation.

Mikulski D, Nowicki M, Drozdz I, Misiewicz M, Koscielny K, Okonski K Front Oncol. 2023; 13:1250355.

PMID: 37829335 PMC: 10565214. DOI: 10.3389/fonc.2023.1250355.

References

Kim S, Ramasamy K, Bouamar H, Lin A, Jiang D, Aguiar R . MicroRNAs miR-125a and miR-125b constitutively activate the NF-κB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Proc Natl Acad Sci U S A. 2012; 109(20):7865-70. PMC: 3356650. DOI: 10.1073/pnas.1200081109. View

Crump M . Management of Hodgkin lymphoma in relapse after autologous stem cell transplant. Hematology Am Soc Hematol Educ Program. 2008; :326-33. DOI: 10.1182/asheducation-2008.1.326. View

Rafiee M, Farsani M, Amiri V, Hajifathali A, Gharehbaghian A, Mohammadi M . Circulatory miR-155 correlation with platelet and neutrophil recovery after autologous hematopoietic stem cell transplantation, a multivariate analysis. Int J Hematol. 2021; 114(2):235-245. DOI: 10.1007/s12185-021-03154-2. View

Smith S, Van Besien K, Carreras J, Bashey A, Cairo M, Freytes C . Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. Biol Blood Marrow Transplant. 2008; 14(8):904-12. PMC: 3353768. DOI: 10.1016/j.bbmt.2008.05.021. View

Corre J, Montes L, Martin E, Perrot A, Caillot D, Leleu X . Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk. Haematologica. 2020; 105(9):e480-483. PMC: 7556617. DOI: 10.3324/haematol.2019.236588. View

Asgarpour K, Shojaei Z, Amiri F, Ai J, Mahjoubin-Tehran M, Ghasemi F . Exosomal microRNAs derived from mesenchymal stem cells: cell-to-cell messages. Cell Commun Signal. 2020; 18(1):149. PMC: 7488404. DOI: 10.1186/s12964-020-00650-6. View

Li G, So A, Sookram R, Wong S, Wang J, Ouyang Y . Epigenetic silencing of miR-125b is required for normal B-cell development. Blood. 2018; 131(17):1920-1930. PMC: 5921965. DOI: 10.1182/blood-2018-01-824540. View

Wang Y, Wei Y, Fan X, Zhang P, Wang P, Cheng S . MicroRNA-125b as a tumor suppressor by targeting MMP11 in breast cancer. Thorac Cancer. 2020; 11(6):1613-1620. PMC: 7262928. DOI: 10.1111/1759-7714.13441. View

Murray M, Rushworth S, Zaitseva L, Bowles K, MacEwan D . Attenuation of dexamethasone-induced cell death in multiple myeloma is mediated by miR-125b expression. Cell Cycle. 2013; 12(13):2144-53. PMC: 3737316. DOI: 10.4161/cc.25251. View

10.

Jiang Y, Luan Y, Chang H, Chen G . The diagnostic and prognostic value of plasma microRNA-125b-5p in patients with multiple myeloma. Oncol Lett. 2018; 16(3):4001-4007. PMC: 6096151. DOI: 10.3892/ol.2018.9128. View

11.

Han B, Wang S, Zhao H . MicroRNA-21 and microRNA-155 promote the progression of Burkitt's lymphoma by the PI3K/AKT signaling pathway. Int J Clin Exp Pathol. 2020; 13(1):89-98. PMC: 7013371. View

12.

Peng B, Theng P, Le M . Essential functions of miR-125b in cancer. Cell Prolif. 2020; 54(2):e12913. PMC: 7848968. DOI: 10.1111/cpr.12913. View

13.

Malard F, Harousseau J, Mohty M . Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis. Cancer Treat Rev. 2016; 52:41-47. DOI: 10.1016/j.ctrv.2016.11.005. View

14.

Chen Y, McCarthy P, Hahn T, Holstein S, Ueda M, Kroger N . Methods to prevent and treat relapse after hematopoietic stem cell transplantation with tyrosine kinase inhibitors, immunomodulating drugs, deacetylase inhibitors, and hypomethylating agents. Bone Marrow Transplant. 2018; 54(4):497-507. DOI: 10.1038/s41409-018-0269-3. View

15.

Kornacker M, Stumm J, Pott C, Dietrich S, Sussmilch S, Hensel M . Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up. Ann Oncol. 2009; 20(4):722-8. DOI: 10.1093/annonc/mdn691. View

16.

Amodio N, Gallo Cantafio M, Botta C, Agosti V, Federico C, Caracciolo D . Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. Cancers (Basel). 2019; 11(2). PMC: 6406286. DOI: 10.3390/cancers11020236. View

17.

Bien E, Balcerska A . Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin's lymphoma. Scand J Immunol. 2009; 70(5):490-500. DOI: 10.1111/j.1365-3083.2009.02313.x. View

18.

Ma Y, Li C, Huang Y, Wang Y, Xia X, Zheng J . Exosomes released from neural progenitor cells and induced neural progenitor cells regulate neurogenesis through miR-21a. Cell Commun Signal. 2019; 17(1):96. PMC: 6698014. DOI: 10.1186/s12964-019-0418-3. View

19.

Misso G, Zarone M, Lombardi A, Grimaldi A, Cossu A, Ferri C . miR-125b Upregulates miR-34a and Sequentially Activates Stress Adaption and Cell Death Mechanisms in Multiple Myeloma. Mol Ther Nucleic Acids. 2019; 16:391-406. PMC: 6479071. DOI: 10.1016/j.omtn.2019.02.023. View

20.

Henry-Amar M, Friedman S, Hayat M, Somers R, Meerwaldt J, Carde P . Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. The EORTC Lymphoma Cooperative Group. Ann Intern Med. 1991; 114(5):361-5. DOI: 10.7326/0003-4819-114-5-361. View